How has the scleritis market evolved, and where is it heading next?
The scleritis market size has grown strongly in recent years. It will grow from $3.60 billion in 2024 to $3.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increase in prevalence of autoimmune disorders, rise in awareness of ocular health, growth in geriatric population, improved access to ophthalmic care, and expanded healthcare infrastructure globally.
The scleritis market size is expected to see strong growth in the next few years. It will grow to $5.54 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growing eye-related health conditions, rising awareness of ocular health, rising healthcare expenditure, expanding research in ophthalmology, rising demand for personalized medicine, and rising treatment option. Major trends in the forecast period include development of targeted biologic therapies, improved immunosuppressive drug formulations, advancements in imaging technologies, adoption of minimally invasive diagnostic tools, adoption of personalized medicine approaches, advancements in drug delivery systems, and AI-driven diagnostic and treatment planning solutions.
Get Your Free Sample of The Global Scleritis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21283&type=smp
What are the key drivers behind the rapid expansion of the scleritis market?
The rising prevalence of autoimmune diseases is expected to drive the growth of the scleritis market going forward. Autoimmune diseases are conditions where the body’s immune system mistakenly attacks its healthy cells and tissues, thinking they are foreign invaders. The rise in autoimmune diseases is linked to genetic predispositions, environmental factors, lifestyle changes, and increased awareness, leading to better diagnosis. Autoimmune diseases cause scleritis by triggering an inflammatory immune response that mistakenly attacks the scleral tissue, leading to pain and redness. For instance, in November 2024, according to the Versorgungsatlas.de, a Germany-based organization, in 2022, out of 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, yielding a raw prevalence rate of 8.61%. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the scleritis market.
What is the segmentation for the scleritis market?
The scleritis market covered in this report is segmented –
1) By Type: Anterior Scleritis, Posterior Scleritis, Other Types
2) By Treatment: Medication, Surgery, Other Treatment
3) By Distribution Channel: Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channel
4) By End-Users: Hospitals, Specialty Clinics, Home Healthcare, Other End-Users
Subsegments:
1) By Anterior Scleritis: Non-Necrotizing Anterior Scleritis, Necrotizing Anterior Scleritis
2) By Posterior Scleritis: Diffuse Posterior Scleritis, Nodular Posterior Scleritis, Scleritis With Choroidal Involvement
3) By Other Types: Chronic Scleritis, Recurrent Scleritis, Infectious Scleritis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/scleritis-global-market-report
Who are the most influential companies in the scleritis market?
Major companies operating in the scleritis market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceuticals USA Inc., Baxter International Inc., Boehringer Ingelheim, Regeneron Pharmaceuticals Inc., Fresenius Kabi USA LLC, Sun Pharmaceutical Industries Ltd., Perrigo Company, Horizon Therapeutics plc, Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mallinckrodt Pharmaceuticals, Alvogen, Accord Healthcare, West-Ward Pharmaceuticals, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Zydus Pharmaceuticals Inc.
What are the most influential trends expected to drive the scleritis market forward?
Major companies operating in the scleritis market are focusing on developing advanced products, such as eye drops, to address the underlying inflammation and provide practical, non-invasive treatment options for patients. Eye drops are liquid solutions designed for direct use in the eyes to manage conditions such as irritation, dryness, inflammation, or infections. For instance, in May 2023, Entod Pharmaceuticals, an India-based pharmaceutical company, launched CYCLOTEARS eye drops in India and globally. This novel therapy for inflammatory eye disease incorporated proprietary SEDDS technology. This product enhances drug delivery and efficacy, offering a pioneering approach to address inflammation in DED. This innovation marks a significant advancement in eye inflammatory treatment, ocular myositis, and scleritis.
What are the major regional insights for the scleritis market, and which region holds the top position?
North America was the largest region in the scleritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Scleritis Market Report 2025 Offer?
The scleritis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Scleritis is an inflammation of the sclera, the white part of the eye. It is often associated with autoimmune diseases and can cause severe eye pain, redness, and potential vision loss if untreated. The diagnosis and treatment of scleritis are crucial to prevent long-term damage to the eye. Early intervention helps reduce the risk of complications such as vision loss.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21283
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
